In addition, molecular interactions between MET and ERBB receptor family signaling pathways may lead to resistance of breast cancer to HER2- and EGFR-targeted therapies [69], implying that MET is promising for the development of oncodriver-targeted therapies. Here, ERBB2 is linked to breast cancer.